– SWITZERLAND, Basel – Noema Pharma, a Swiss-based clinical-stage company targeting orphan central nervous system diseases, today announced the appointments of Catherine Moukheibir and Dr. Ilise Lombardo (MD) to its Board as Independent Directors, expanding the board after the recent appointment of Dr. Jeffrey Jonas as its Chairman.
“I am very pleased to welcome Catherine and Ilise to the board of Noema Pharma. They are joining us at a pivotal time, while we are making significant progress in our clinical, structural and financial development,” said CEO, Luigi Costa. “Catherine and Ilise are highly respected executives in innovative life sciences companies with exceptional track records. Their considerable experience and knowledge will make them invaluable members of our board. We look forward to their advice, which will strengthen our Company’s leadership and support its mission to positively impact the lives of patients, as well as continuing to create shareholder value.”
Ms. Moukheibir has extensive experience in finance, capital markets, and life sciences, having held several senior executive and board-level positions in the biotech and pharmaceutical sectors. Dr. Lombardo is currently CMO at Kriya Therapeutics and has previously led clinical development and medical affairs programs with a focus on diseases of the nervous system.
Ms. Moukheibir and Dr. Lombardo join current board members:
- Darren Carroll from Polaris Partners,
- Antoine Papiernik from Sofinnova Partners
- Arthur Franken from Gilde Healthcare.
About Catherine Moukheibir
Catherine Moukheibir currently serves on the Board of Directors at DNA Script, Asceneuron, Biotalys, CMR Surgical, Ironwood Pharmaceuticals, and Orphazyme. She has previously held board memberships at Kymab, GenKyoTex, Cerenis, Zealand, Ablynx, and Creabilis. Ms. Moukheibir was Chair and CEO of MedDay Pharmaceuticals and has also held senior executive positions at Innate Pharma, Movetis, and Zeltia Group.
“I am thrilled to be part of Noema’s effort to develop groundbreaking therapies for the most debilitating symptoms in orphan conditions of the brain and central nervous system,” commented Catherine Moukheibir. “Last year’s successful Series A funding round has put the company in a strong financial position to advance its clinical mission and the company’s development to the next stage.”
Before moving into the life sciences industry, Ms. Moukheibir worked in investment banking. She received an MBA and a Master’s in Economics from Yale University.
About Ilise Lombardo
Ilise Lombardo is Chief Medical Officer at gene therapy company Kriya Therapeutics, where she leads the clinical and medical departments advancing a pipeline of gene therapy candidates across multiple therapeutic areas. Before joining Kriya, Dr. Lombardo was co-founder and Chief Medical Officer of epilepsy-focused company Arvelle Therapeutics. She has also held senior roles in clinical and medical development at Axovant Sciences, Forum Pharmaceuticals, and Pfizer.
“I am delighted to be joining Noema Pharma’s board and I’m looking forward to working with Noema’s dedicated and talented executive team,” said Dr. Ilise Lombardo. “It is an exciting time for the Company, as it has recently initiated its first clinical trial in patients with Tourette syndrome and is planning to start two additional trials in the near future. These product candidates have the potential to offer new solutions for patients with debilitating conditions and I am thrilled to share my input into the various development efforts.”
She has a medical degree from Yale University, an M.Phil from the University of Cambridge, and a bachelor’s degree from Brown University.
About Noema Pharma
Noema Pharma is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, a mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex and severe pain in Trigeminal Neuralgia. NOE-105, a PDE10A inhibitor, is currently in Phase 2a investigated in patients with Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, a mGluR2/3 inhibitor, and NOE-115, a triple reuptake inhibitor. Noema Pharma was founded with the leading venture capital firm Sofinnova Partners. Investors include Polaris Partners, Gilde Healthcare, Invus, and Biomed Partners.
For more information: https://noemapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.